Assertio Therapeutics Inc (ASRT)

Assertio Therapeutics (ASRT) Stock Price & Analysis


ASRT Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.86 - $7.00
Previous Close$5.78
Average Volume (3M)1.88M
Market Cap
Enterprise Value$323.18M
Total Cash (Recent Filing)$64.94M
Total Debt (Recent Filing)$66.87M
Price to Earnings (P/E)3.3
May 04, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.75
Shares Outstanding48,293,613
10 Day Avg. Volume1,840,143
30 Day Avg. Volume1,883,551
Standard Deviation0.27
Financial Highlights & Ratios
Price to Book (P/B)-4.22
Price to Sales (P/S)2.26
Price to Cash Flow (P/CF)4.30
P/FCF Ratio6.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.07
Enterprise Value/Gross Profit2.35
Enterprise Value/Ebitda4.47
Price Target Upside41.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Assertio Therapeutics Inc’s price range in the past 12 months?
Assertio Therapeutics Inc lowest stock price was $1.86 and its highest was $7.00 in the past 12 months.
    What is Assertio Therapeutics Inc’s market cap?
    Currently, no data Available
    When is Assertio Therapeutics Inc’s upcoming earnings report date?
    Assertio Therapeutics Inc’s upcoming earnings report date is May 04, 2023 which is in 44 days.
      How were Assertio Therapeutics Inc’s earnings last quarter?
      Assertio Therapeutics Inc released its earnings results on Mar 08, 2023. The company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.482 by -$0.162.
        Is Assertio Therapeutics Inc overvalued?
        According to Wall Street analysts Assertio Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Assertio Therapeutics Inc pay dividends?
          Assertio Therapeutics Inc does not currently pay dividends.
          What is Assertio Therapeutics Inc’s EPS estimate?
          Assertio Therapeutics Inc’s EPS estimate is $0.17.
            How many shares outstanding does Assertio Therapeutics Inc have?
            Assertio Therapeutics Inc has 55,578,545 shares outstanding.
              What happened to Assertio Therapeutics Inc’s price movement after its last earnings report?
              Assertio Therapeutics Inc reported an EPS of $0.32 in its last earnings report, missing expectations of $0.482. Following the earnings report the stock price went up 11.745%.
                Which hedge fund is a major shareholder of Assertio Therapeutics Inc?
                Among the largest hedge funds holding Assertio Therapeutics Inc’s share is First Eagle Investment Management LLC. It holds Assertio Therapeutics Inc’s shares valued at 3M.


                  Assertio Therapeutics Stock Smart Score

                  The Assertio Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Assertio Therapeutics Inc

                  Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Citius Pharmaceuticals
                  Zevra Therapeutics
                  Prophase Labs

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis